Response to FDA Questions
Data support accurate self-selection of consumers following physician diagnosis
- Physicians and CIU sufferers conclude patients can self-recognize recurrent episodes
- Self recognition study demonstrates accurate self recognition following initial diagnosis
Labeling for ClaritinŽ can be developed for proper OTC use for CIU